mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
暂无分享,去创建一个
M. Nussenzweig | P. Bieniasz | A. Hurley | P. Bjorkman | R. Casellas | A. Gazumyan | Y. Weisblum | R. Colbert | Thiago Y. Oliveira | T. Hatziioannou | C. Gaebler | C. Barnes | Kathryn E Huey-Tubman | F. Muecksch | Shlomo Finkin | F. Schmidt | M. Caskey | I. Shimeliovich | Kristie M Gordon | Victor Ramos | Zijun Wang | Juan P Dizon | K. West | Roshni Patel | Zhi Yang | M. Abernathy | Jianliang Xu | M. Cipolla | Katrina G Millard | Justin Da Silva | Dennis J Schaefer-Babajew | Martina Turroja | J. Lieberman | Justin Da Silva | Cecille Unson-O’Brien | Katrina G. Millard | R. Patel
[1] E. Hodcroft,et al. Genetic Variants of SARS-CoV-2-What Do They Mean? , 2021, JAMA.
[2] M. Nussenzweig,et al. Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo , 2020, The Journal of experimental medicine.
[3] John D. Davis,et al. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 , 2020, The New England journal of medicine.
[4] P. Dormitzer,et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.
[5] J. Mascola,et al. Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination , 2020, The New England journal of medicine.
[6] Sarah K. Hilton,et al. Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition , 2020, Cell Host & Microbe.
[7] C. Rice,et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants , 2020, bioRxiv.
[8] M. Nussenzweig,et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies , 2020, Nature.
[9] M. Nussenzweig,et al. All eyes on a hurdle race for a SARS-CoV-2 vaccine , 2020, Nature.
[10] P. Dormitzer,et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses , 2020, Nature.
[11] M. Beltramello,et al. Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms , 2020, Science.
[12] F. Krammer. SARS-CoV-2 vaccines in development , 2020, Nature.
[13] M. Beltramello,et al. Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology , 2020, Cell.
[14] Ralf Bartenschlager,et al. Structures and distributions of SARS-CoV-2 spike proteins on intact virions , 2020, Nature.
[15] J. Mascola,et al. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates , 2020, The New England journal of medicine.
[16] Ilya J. Finkelstein,et al. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes , 2020, Science.
[17] J. Sodroski,et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike , 2020, Nature.
[18] C. Rice,et al. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses , 2020, The Journal of experimental medicine.
[19] Xuguang Li,et al. The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity , 2020, Cell.
[20] Lisa E. Gralinski,et al. Potently neutralizing and protective human antibodies against SARS-CoV-2 , 2020, Nature.
[21] J. Mascola,et al. An mRNA Vaccine against SARS-CoV-2 — Preliminary Report , 2020, The New England journal of medicine.
[22] M. Nussenzweig,et al. Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies , 2020, Cell.
[23] D. Burton,et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model , 2020, Science.
[24] C. Rice,et al. Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals , 2020, Nature.
[25] Linqi Zhang,et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection , 2020, Nature.
[26] J. Greenbaum,et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals , 2020, Cell.
[27] Amalio Telenti,et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody , 2020, Nature.
[28] X. Xie,et al. Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells , 2020, Cell.
[29] M. V. van Breemen,et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability , 2020, Science.
[30] C. Cunningham-Rundles,et al. A serological assay to detect SARS-CoV-2 seroconversion in humans , 2020, Nature Medicine.
[31] Yicheng Guo,et al. cAb-Rep: A Database of Curated Antibody Repertoires for Exploring Antibody Diversity and Predicting Antibody Prevalence , 2019, Frontiers in immunology.
[32] James E. Crowe,et al. High frequency of shared clonotypes in human B cell receptor repertoires , 2019, Nature.
[33] D. Burton,et al. Commonality despite exceptional diversity in the baseline human antibody repertoire , 2018, Nature.
[34] Nico Pfeifer,et al. Safety and anti-viral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals , 2018, Nature Medicine.
[35] Nico Pfeifer,et al. Combination therapy with anti-HIV-1 antibodies maintains viral suppression , 2018, Nature.
[36] Thomas C Terwilliger,et al. A fully automatic method yielding initial models from high-resolution electron cryo-microscopy maps , 2018, Nature Methods.
[37] Conrad C. Huang,et al. UCSF ChimeraX: Meeting modern challenges in visualization and analysis , 2018, Protein science : a publication of the Protein Society.
[38] David J. Fleet,et al. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination , 2017, Nature Methods.
[39] Stefan Elbe,et al. Data, disease and diplomacy: GISAID's innovative contribution to global health , 2017, Global challenges.
[40] Steven H. Kleinstein,et al. Change-O: a toolkit for analyzing large-scale B cell immunoglobulin repertoire sequencing data , 2015, Bioinform..
[41] William S. DeWitt,et al. Replicate immunosequencing as a robust probe of B cell repertoire diversity , 2014, 1410.0350.
[42] H. Lehrach,et al. Onset of Immune Senescence Defined by Unbiased Pyrosequencing of Human Immunoglobulin mRNA Repertoires , 2012, PloS one.
[43] P. Emsley,et al. Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.
[44] Nichole E Carlson,et al. Duration of humoral immunity to common viral and vaccine antigens. , 2007, The New England journal of medicine.
[45] David N Mastronarde,et al. Automated electron microscope tomography using robust prediction of specimen movements. , 2005, Journal of structural biology.
[46] H. Guy. Amino acid side-chain partition energies and distribution of residues in soluble proteins. , 1985, Biophysical journal.
[47] R. Doolittle,et al. A simple method for displaying the hydropathic character of a protein. , 1982, Journal of molecular biology.